In the original article, there was a mistake in Figure [1](#F1){ref-type="fig"} as published. The chirality of L-AP4 and LSP1-2111 was incorrect. pEC~50~ values have also been corrected for LSP1-2111 in Table [1](#T1){ref-type="table"}. The authors apologize for these errors and state that they do not change the scientific conclusions of the article in any way. The original article has been updated.
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Summary of current tool compounds used to study mGlu~7~.

  **Name (\#)**        **Type**                 **mGlu~**7**~ pEC~**50**~/pIC~**50**~**   **mGlu~**8**~ pEC~**50**~/pIC~**50**~**   **mGlu~**4**~ pEC~**50**~/pIC~**50**~**   **mGlu~**6**~ pEC~**50**~/pIC~**50**~**   **Source**
  -------------------- ------------------------ ----------------------------------------- ----------------------------------------- ----------------------------------------- ----------------------------------------- ------------------------------------------------------------------
  L-AP4 **(1)**        Orthosteric agonist      3.47 (PIH)                                6.53 (PIH)                                7.00 (PIH)                                5.62 (PIH)                                Acher et al., [@B2]; Selvam et al., [@B12]
                                                3.61 (Ca^2+^)                             6.53 (Ca^2+^)                             6.89 (Ca^2+^)                             6.00 (Ca^2+^)                             
  LSP4-2022 **(2)**    Orthosteric agonist      4.34 (Ca^2+^)                             4.54 (Ca^2+^)                             6.96 (Ca^2+^)                             5.36 (Ca^2+^)                             Acher et al., [@B2]; Goudet et al., [@B4]; Selvam et al., [@B12]
  LSP1-2111 **(3)**    Orthosteric agonist      4.28 (PIH)                                4.18 (PIH)                                5.66 (PIH)                                5.77 (PIH)                                Selvam et al., [@B12]
                                                4.00 (Ca^2+^)                             4.71 (Ca^2+^)                             6.05 (Ca^2+^)                             5.49 (Ca^2+^)                             
  LSP2-9166 **(4)**    Orthosteric agonist      5.71 (Ca^2+^)                             4.25 (Ca^2+^)                             7.22 (Ca^2+^)                             not reported                              Acher et al., [@B2]
  VU0422288 **(5)**    Group III PAM            6.85 (Ca^2+^)                             6.93 (Ca^2+^)                             6.98 (Ca^2+^)                             not reported                              Jalan-Sakrikar et al., [@B5]
  VU0155094 **(6)**    Group III PAM            5.80 (Ca^2+^)                             6.07 (Ca^2+^)                             5.48 (Ca^2+^)                             not reported                              Jalan-Sakrikar et al., [@B5]
  ADX88178 **(7)**     mGlu~4/8~ PAM            \>4.52 (Ca^2+^)                           5.66 (Ca^2+^)                             8.46 (Ca^2+^)                             \>5                                       Le Poul et al., [@B8]
  ADX71743 **(8)**     mGlu~7~ NAM              7.20 (human, Ca^2+^)                      inactive                                  inactive                                  inactive                                  Kalinichev et al., [@B6]
                                                7.06 (rat, Ca^2+^)                        inactive                                  inactive                                  inactive                                  
  AMN082 **(9)**       Allosteric agonist       6.59 (GTPγS)                              \>5 (GTPγS)                               \>5 (GTPγS)                               \>5 (GTPγS)                               Mitsukawa et al., [@B9]
  XAP044 **(10)**      Antagonist               5.26 (cAMP)                               4.48 (cAMP)                               inactive                                  inactive                                  Gee et al., [@B3]
                                                5.55 to 5.46 (GTPγS)                                                                                                                                                    
  LY341495 **(11)**    Orthosteric antagonist   6.00 (cAMP)                               6.76 (cAMP)                               4.66 (cAMP)                               not reported                              Kingston et al., [@B7]
  MMPIP **(12)**       mGlu~7~ NAM              6.66 (cAMP)                               \>5 (cAMP)                                \>5 (cAMP)                                not reported                              Suzuki et al., [@B13]
                                                7.15 (Ca^2+^)                                                                                                                                                           Niswender et al., [@B10]
                                                6.14 (Thallium)                                                                                                                                                         Niswender et al., [@B10]
  VU6010608 **(13)**   mGlu~7~ NAM              6.12 (Ca^2+^)                             \>5 (Ca^2+^)                              \>5 (Ca^2+^)                              inactive (\>5)                            Reed et al., [@B11]
  VU6005649 **(14)**   mGlu~7/8~ PAM            6.19 (Ca^2+^)                             5.59 (Ca^2+^)                             \>5 (Ca^2+^)                              inactive                                  Abe et al., [@B1]

*NAM, negative allosteric modulator; PAM, positive allosteric modulator; EC~50~, effective concentration 50; IC~50~, inhibitory concentration 50. Assay type is indicated in parentheses: PIH, Phosphatidylinositol hydrolysis; cAMP, cAMP accumulation; Ca^2+^, Calcium mobilization; GTPγS, GTPγS binding*.
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